Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes. - Wikidata - awgldk - TriplyDB

Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes.

Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes.

http://www.wikidata.org/entity/Q37269476

about

Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus.Sitagliptin and heart failure hospitalization in patients with type 2 diabetes Metformin use and cervical cancer risk in female patients with type 2 diabetes Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus.Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes.Metformin and lung cancer risk in patients with type 2 diabetes mellitus.Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.Sitagliptin and oral cancer risk in type 2 diabetes patients.

P2860

Q37274957-9E13E829-C3C1-4ECF-AF31-DF91365115C9 Q37641835-1912C4F5-F712-4B65-B46B-EDD2051E58BB Q37644891-25001532-220E-4837-82CA-8A263DF45A1A Q37745840-1B779E29-5EE1-40BA-A199-6E0EBAE39A0E Q37745926-49E1A38D-527E-4594-9E8B-6D8014E2FE86 Q41092838-C96232A2-1A47-47F4-8846-82ED65617FA2 Q41422603-046C323F-32CC-48BA-B098-ED8137827580 Q47096984-5A858073-B83D-429C-ACD1-4F5E22E5254A

P2860

Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes.

http://www.wikidata.org/entity/Q37269476

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 March 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes.

@en

Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes.

@nl

type

label

Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes.

@en

Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes.

@nl

prefLabel

Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes.

@en

Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes.

@nl

P1433

Q37269476-5730B9E8-ABDA-4961-8288-350193AAC99D

P1476

Q37269476-EA9A1B71-3B25-4FC6-8A16-DE8930B8C13A

P2093

Q37269476-252700EC-9627-4831-B56E-7EEB85A03F67

P2860

Q37269476-1537C97F-F5C2-4B32-B564-BC7F11ADF7F9

Q37269476-27237001-8027-435D-8968-22A151A3C340

Q37269476-38612B37-8FB0-4DCA-91E9-EF33D5CAFB76

Q37269476-4E489C62-14D6-4B15-9E38-BD6D2F94E582

Q37269476-6EB0E65F-4F82-4EDA-A5A7-4E70DDC1FAD4

Q37269476-78C5A576-11E5-44FC-9F84-D73876B292EA

Q37269476-7FDFD004-7191-42B8-870A-62FC61D83A76

Q37269476-81783E90-6FFD-42C7-A924-5C18484093E9

Q37269476-8281F717-D9E5-4750-B451-43AB78E30553

Q37269476-88D3CDCB-8E41-4D8F-A7C4-071C4D00A33E

P304

Q37269476-20DCFB2D-ABE3-4E0E-AC6A-AD17420B82DF

P31

Q37269476-15B2C9F9-B7AF-46B6-B58E-AFC4824EC009

P356

Q37269476-C781E7A1-1937-4F71-BE56-4E928BB6C520

P407

Q37269476-A22BD9E6-8287-48DB-BF42-D7BF48238DD0

P433

Q37269476-F4CCDEEC-1825-4706-A011-7603D3E4E8EE

P478

Q37269476-387B2DA5-9915-412E-A48B-9C5EFD4DFD04

P577

Q37269476-954CB61C-DBE1-475A-B54D-8F10552708B5

P5875

Q37269476-91475C9A-73E6-4454-B322-4C806F882505

P698

Q37269476-1D4FE2A8-501F-4C3D-A99D-813834228CCD

P921

Q37269476-B445C892-F689-43E1-866D-16D8797525BC

P932

Q37269476-8949B5B6-CDE1-439F-9171-0C1B169EA749

P356

ONCOTARGET.8399

P1433

P1476

Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes.

@en

P2093

Chin-Hsiao Tseng

http://www.w3.org/2001/XMLSchema#string

P2860

Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes.

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

Pioglitazone and bladder cancer: a population-based study of Taiwanese.

A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer

Diabetes and thyroid cancer risk: literature review.

Glucagon like peptide-1 receptor expression in the human thyroid gland

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.

Metformin may reduce oral cancer risk in patients with type 2 diabetes

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?

Immortal time bias in pharmaco-epidemiology.

P304

24871-24879

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.8399

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

299460018

http://www.w3.org/2001/XMLSchema#string

P698

27029076

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5029749

http://www.w3.org/2001/XMLSchema#string